Cholinesterase inhibitors for treatment of dementia associated with Parkinson's disease.
Cummings
J L
JL
D002800:Cholinesterase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D015897:Comorbidity; D018592:Cross-Over Studies; D003430:Cross-Sectional Studies; D003704:Dementia / Q000188:drug therapy* / Q000453:epidemiology; D000077265:Donepezil; D004311:Double-Blind Method; D006801:Humans; D007189:Indans / Q000009:adverse effects / Q000627:therapeutic use*; D008609:Mental Status Schedule; D009483:Neuropsychological Tests; D017063:Outcome Assessment, Health Care; D010300:Parkinson Disease / Q000188:drug therapy* / Q000453:epidemiology; D048448:Phenylcarbamates / Q000009:adverse effects / Q000627:therapeutic use*; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D000068836:Rivastigmine
D002800:Cholinesterase Inhibitors; D007189:Indans; D048448:Phenylcarbamates; D010880:Piperidines; D000077265:Donepezil; D000068836:Rivastigmine